Polygon Health

12/09/2025

Going into Year End - Here's two events that may be of interest.

12/04/2025

New Series: Mythbusting Clinical Trials.
Learn More: In Comments

12/03/2025

11/25/2025

Here's whats new in MM Research this week:

Want to learn more about Clinical Trials? Link in Comments Below.

11/21/2025

We had a great Clinical Trial Pod w/ Ozlem from Massive Bio - a Polygon Health partner. Enjoy! Check out our IG for more clips.

(link to learn more about Clinical Trials in comments below)

11/21/2025

The 67th ASH Annual Meeting will be held virtually and in person at the Orange County Convention Center in Orlando, Florida, December 6 - 9, 2025.

11/11/2025

LIVE Clinical Trial Podcast this Wednesday (11/12) at 11:30AM. Bring your Questions about Behind the Scenes of Clinical Trials.

ZOOM link in Comments section.

11/07/2025

Exciting news for our myeloma community! 🩸

The American Society of Hematology (ASH) 2025 Annual Meeting & Exposition is happening December 6–9 in Orlando, Florida—with both in-person and online options! ASH 2025 will feature a strong focus on multiple myeloma, with sessions on cutting-edge research, new treatments, and patient care.

Let’s connect, learn, and support each other during this major event—whether you plan to attend in person or join virtually!

🔗 More info in the comments.

11/04/2025

*Phase 1 Autologous CAR-T Clinical Trial Results: Hopeful Responses for Multiple Myeloma Patients*

Recent Phase 1 trials using autologous CAR-T therapies are delivering hope to patients battling tough cancers, especially multiple myeloma. Key Takeaways:

High response rates: Multiple myeloma patients in these trials are experiencing strong overall and complete responses, even if they’ve relapsed or run out of options with other treatments.

Advanced targeting: New bicistronic CAR-Ts are designed to target two antigens (CD19 and CD20), reducing the likelihood that cancer cells will escape detection and improving safety. This could mean more myeloma patients may have access to care in outpatient settings.

Expanded access: FDA-approved autologous CAR-Ts, like Yescarta, are now showing promising efficacy and safety whether patients are eligible for transplant or not, opening doors for more individuals with myeloma to try potentially curative therapy.

These findings highlight the crucial role clinical trials play for multiple myeloma patients—not only as access points for personalized, cutting-edge treatments, but also as opportunities to help advance breakthrough therapies for the entire myeloma community. Participating in trials helps bring hope and innovation closer to all those affected by this disease.

Interested to Learn More? Link in Comments.

Send a message to learn more

10/31/2025

VIRTUAL WALK/RUN | IN PERSON in HOUSTON - Sign Up to Join. Link in Comments

10/28/2025

CLINICAL TRIAL NEWS:
New Myeloma Drug Combo Gives Fresh Hope for Patients: FDA Approves Blenrep + Velcade + Dexamethasone After Prior Treatments

If your multiple myeloma has come back or stopped responding after at least two different treatments, there’s a new option: a combination of Blenrep (belantamab mafodotin), Velcade (bortezomib), and dexamethasone.

This newly approved drug combo was tested in a large clinical trial with real patients. Compared to one of the most common options, it cut the risk of death in half and more than tripled the time before the cancer grew again—often giving many extra months and even years of life.

WHY IT MATTERS?

This approval is for people running out of choices, showing research continues to create new lifelines.

Clinical trials like DREAMM-7—thanks to patients who volunteered—make new treatments like this available.

While side effects are still present (especially eye issues), doctors see this as a meaningful advance, with the treatment also available in local community centers for easier access.

BOTTOM LINE:
Progress like this only happens because myeloma fighters step up to join trials. Every advance offers real hope for more time and better options at every stage of the journey.

INTERESTED IN LEARNING MORE? Links in Comment Below

Send a message to learn more